Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence
|
Aug 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes
|
Apr 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016
|
Nov 2016
|
Leuk Res
|
aplastic anemia
|
The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes
|
Jan 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
|
Aug 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
|
Mar 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Impact of tobacco usage on disease outcome in myelodysplastic syndromes
|
Apr 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms.
|
Jan 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q-New prognostic markers are needed
|
Dec 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease
|
Jul 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|